Developmental potential of slow-developing embryos: day-5 morulae compared with day-5 cavitating morulae.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
01 2019
Historique:
received: 21 06 2018
revised: 24 08 2018
accepted: 28 08 2018
pubmed: 18 11 2018
medline: 26 4 2019
entrez: 17 11 2018
Statut: ppublish

Résumé

To describe and compare the ongoing pregnancy rate between morulae and cavitating morulae (CAVM) transferred on day 5, to describe and compare the blastulation rate between day 5 morulae and CAVM, and to describe the pregnancy rate of these slow-developing blastocysts during a frozen embryo transfer (FET) cycle. Retrospective cohort study. Single tertiary care medical center. Delayed-development embryos: 3,321 cycles that included 10,304 embryos on day 5 that were cultured until day 6. Development of morula and CAVM to the blastocyst stage. Blastulation rate. The fresh embryo transfers comprised 186 patients with 82 embryos at the morula stage and 104 embryos at the CAVM stage. The pregnancy rate (15.8% vs. 21.1%) and the ongoing pregnancy rate (15.8% vs. 17.3%) were comparable between the groups. The study group included 10,304 day-5 delayed embryos: 5,395 morulae and 4,909 CAVM on day 5. The blastulation rate was statistically significantly higher in the CAVM group compared with the morula group (39.2% vs. 20.4%). We included 201 FET cycles: 77 warmed blastocysts that developed from a morula on day 5 and 124 warmed blastocysts that developed from CAVM on day 5. The clinical pregnancy rate was comparable between the two groups per embryo transfer (21.3% vs. 24.7%). Transferring of fresh, slow-developing embryos seems to improve the cycle outcomes compared with culturing for another day and then vitrifying and thawing later.

Identifiants

pubmed: 30442415
pii: S0015-0282(18)31892-2
doi: 10.1016/j.fertnstert.2018.08.053
pii:
doi:

Substances chimiques

Estradiol 4TI98Z838E

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-111

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Jigal Haas (J)

TRIO Fertility Partners, Division of Reproductive Sciences, University of Toronto, Toronto, Ontario, Canada; IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel- Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: jigalh@hotmail.com.

Jim Meriano (J)

TRIO Fertility Partners, Division of Reproductive Sciences, University of Toronto, Toronto, Ontario, Canada.

Rawad Bassil (R)

TRIO Fertility Partners, Division of Reproductive Sciences, University of Toronto, Toronto, Ontario, Canada.

Eran Barzilay (E)

TRIO Fertility Partners, Division of Reproductive Sciences, University of Toronto, Toronto, Ontario, Canada; IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel- Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Eran Zilberberg (E)

TRIO Fertility Partners, Division of Reproductive Sciences, University of Toronto, Toronto, Ontario, Canada.

Robert F Casper (RF)

TRIO Fertility Partners, Division of Reproductive Sciences, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH